Rigel Pharmaceuticals
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 900, South San Fran...Phone Number
(650) 624-1100Website
www.rigel.comRevenue
$299.8 MillionStock Symbol
RIGLIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
2
1
1
1
1
About Rigel Pharmaceuticals
Founded in 1996, Rigel Pharmaceuticals is a drug development company that specializes in the discovery and development of small-molecule drugs for the treatment of autoimmune diseases, muscle disorders and inflammatory diseases. Rigel Pharmaceuticals is headquartered in San Francisco, California.Explore more
Rigel Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rigel Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Rigel Pharmaceuticals recently announced quarterly report
Check if Rigel Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Rigel Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Rigel Pharmaceuticals
Rigel Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Rigel Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Rigel Pharmaceuticals has new funding data
Check out if Rigel Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Rigel Pharmaceuticals
Compare insights from companies similar to Rigel Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rigel Pharmaceuticals
$299.8M
51-200
Public
$888.4M
1996
JL
Joseph LasagaExecutive Vice President & Chief Business Officer
Company Profile Activity
Activity Insights
Rigel Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rigel Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rigel Pharmaceuticals.
Rigel Pharmaceuticals financials insights
Gather financial insights about Rigel Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Stock Offering
$127.5M
2009
Stock Offering
$101.5M
2011
Stock Offering
$140.5M
2012
Stock Offering
$135.7M
2017
Stock Offering
$46M
Stock Offering
$69.7M
2018
Stock Offering
$58.4M
2019
Debt
$60M
Rigel Pharmaceuticals Tech Stack
A closer look at the technologies used by Rigel Pharmaceuticals
Most Recent Scoops
Person-Based
Events
Executive Move
Executive Moves, Board of Directors
Facilities Relocation / Expansion
Rigel Pharmaceuticals is planning to move offices in January 2027. The move will impact approximately 30 employees at the existing office located at 611 Gateway Blvd, South San Francisco, CA.
Facilities Relocation/Expansion
Open Position
Open Position
Rigel Pharmaceuticals News & Media
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview...Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with...Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company...Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rigel Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 1996, Rigel Pharmaceuticals is a drug development company that specializes in the discovery and development of small-molecule drugs for the treatment of autoimmune diseases, muscle disorders and inflammatory diseases. Rigel Pharmaceuticals is headquartered in San Francisco, California.... Read More
